shelf(0)

No. 053 · Combos · Peptide Blend

Sermorelin + Ipamorelin

— Not ranked · combination how tiers work →
  • Not approved as a combo
  • WADA ✗ S2
Compare Cite
Fingerprint combination
Sermorelin + Ipamorelin (no defined sequence)

Combos are blends of separate compounds, so there is no single sequence. This ring motif is decorative — open a component for its fingerprint.

01

Quick answers

What is Sermorelin + Ipamorelin?
A well-tolerated GH secretagogue blend pairing the bioidentical GHRH fragment Sermorelin with the selective GHRP Ipamorelin for balanced growth hormone stimulation. Sermorelin (GHRH 1-29) plus ipamorelin.
What is in Sermorelin + Ipamorelin?
Sermorelin + Ipamorelin typically combines Sermorelin and Ipamorelin. Commercial products vary.
How strong is the evidence for Sermorelin + Ipamorelin?
It is not ranked. A PubMed search found no published studies of this combination; only reviews mention it. Sermorelin was once FDA-approved (Geref, since discontinued); ipamorelin has small human pharmacology studies.
Is Sermorelin + Ipamorelin FDA-approved?
No. Sermorelin + Ipamorelin is not an approved product; no regulator has reviewed the combination.
Is Sermorelin + Ipamorelin banned in sport?
Yes. Sermorelin + Ipamorelin is prohibited in sport by the World Anti-Doping Agency under S2 (peptide hormones, growth factors, related substances and mimetics).
How does Sermorelin + Ipamorelin work?
This blend combines sermorelin (bioidentical GHRH 1-29 acting via the GHRH receptor/cAMP pathway) with ipamorelin (selective ghrelin receptor agonist acting via IP3/PKC). The dual-pathway synergy amplifies GH pulses while both components maintain selectivity: sermorelin preserves feedback physiology and ipamorelin avoids cortisol/prolactin elevation.
What is known about the safety of Sermorelin + Ipamorelin?
Both components have established clinical safety histories. Sermorelin was previously FDA-approved (Geref).

Last reviewed · editorial policy · markdown

02

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

Not ranked: combinations have no published studies of their own. See the components below.

A PubMed search found no published studies of this combination; only reviews mention it. Sermorelin was once FDA-approved (Geref, since discontinued); ipamorelin has small human pharmacology studies.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

03

At a glance

Routes studied
Subcutaneous, Intramuscular Routes used in published research
FDA
Not approved as a combination
WADA
Prohibited · S2 Peptide hormones, growth factors, related substances and mimetics
04

Overview

A well-tolerated GH secretagogue blend pairing the bioidentical GHRH fragment Sermorelin with the selective GHRP Ipamorelin for balanced growth hormone stimulation.

Research status No published studies of the combination; sermorelin was FDA-approved (Geref, since discontinued) and ipamorelin has small human pharmacokinetic studies

05

Mechanism

This blend combines sermorelin (bioidentical GHRH 1-29 acting via the GHRH receptor/cAMP pathway) with ipamorelin (selective ghrelin receptor agonist acting via IP3/PKC). The dual-pathway synergy amplifies GH pulses while both components maintain selectivity: sermorelin preserves feedback physiology and ipamorelin avoids cortisol/prolactin elevation.

06

Effects reported in research

These outcomes are attributed to the individual components. The combination itself has not been studied.

  • Balanced GH elevation via dual pathways
  • Improved sleep quality and recovery
  • Enhanced fat metabolism
  • Minimal side effects due to selectivity
07

Safety & unknowns

Both components have established clinical safety histories. Sermorelin was previously FDA-approved (Geref). Ipamorelin has Phase II data. Combined profile expected to be very well-tolerated. Common side effects: headache, flushing, injection site irritation. Not FDA-approved as a combination.

Unknowns. The combination itself has not been studied; interactions between its components are unknown.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

08

Studies [2]

  1. Preclinical 1998

    Ipamorelin, the first selective growth hormone secretagogue

    Raun K, Hansen BS, Johansen NL, et al. European Journal of Endocrinology

    Rat and swine study on the ipamorelin component showing selective GH release without increases in ACTH or cortisol.

    [pubmed] [doi]

  2. Clinical trial 1997

    Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men

    Vittone J, Blackman MR, Busby-Whitehead J, et al. Metabolism

    Six-week study of nightly GHRH 1-29 (the sermorelin sequence) in 11 elderly men: some muscle-strength measures improved, with no change in body composition or metabolic measures.

    [pubmed] [doi]

09

Components

Sermorelin Tier S · Approved S Ipamorelin Tier A · Controlled human trials A
11

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

12

Cite this entry

$ cite --format=apa

peptidemeta. (2026). Sermorelin + Ipamorelin. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/sermorelin-ipamorelin/

$ cite --format=bibtex 
@misc{peptidemeta-sermorelin-ipamorelin,
  title = {Sermorelin + Ipamorelin},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/sermorelin-ipamorelin/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open